American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Barinthus Biotherapeutics plc. (BRNS)

$0.74 -2.49% NASDAQ: BRNS · 15-min delayed

GERMANTOWN, Maryland
Public · NASDAQ: BRNS
14 employees

Visit website Follow

$24.6MMarket cap

$0Revenue · FY2025

-$66.4MNet income

14Employees

BRNSNASDAQ

2021IPO

About Barinthus Biotherapeutics plc.

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: BRNS
Employees: 14
IPO date: Apr 30, 2021
Headquarters: 20400 CENTURY BLVD
GERMANTOWN, Maryland 20874
Phone: 44 (0) 1865 818808
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: BRNS Nasdaq
SEC CIK: 1828185
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Barinthus Biotherapeutics plc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/barinthus-biotherapeutics-plc/"><img src="https://americancompanies.com/badge/barinthus-biotherapeutics-plc.svg" alt="Barinthus Biotherapeutics plc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Barinthus Biotherapeutics plc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $0
Net income: -$66.4M
Total assets: $98.2M
Market cap: $24.6M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BRNS

$0.74 -2.49%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.54 $1.58

52-week range

Market cap: $24.6M
Shares outstanding: 33.2M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Apr 30, 2021

Barinthus Biotherapeutics plc. (BRNS) Stock Price

Reported a net loss of $66.4M in FY2025.
Trading 53% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Barinthus Biotherapeutics plc..

Write a review

Newsroom

News about Barinthus Biotherapeutics plc.

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics GlobeNewswire Inc. · 2026-08-24 · neutral Halper Sadeh LLC Encourages HFWA, BRNS, FITB Shareholders to Contact the Firm to Discuss Their Rights GlobeNewswire Inc. · 2025-11-20 · neutral Halper Sadeh LLC Encourages HFWA, FITB, AVDL, BRNS Shareholders to Contact the Firm to Discuss Their Rights GlobeNewswire Inc. · 2025-11-19 · neutral BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY) GlobeNewswire Inc. · 2025-10-16 · neutral $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Barinthus Biotherapeutics plc (NASDAQ: BRNS) GlobeNewswire Inc. · 2025-10-07 · neutral SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECO, BRNS, VRNT on Behalf of Shareholders GlobeNewswire Inc. · 2025-10-04 · neutral

News & sentiment via Polygon.io

FAQ

Barinthus Biotherapeutics plc.: frequently asked questions

Is Barinthus Biotherapeutics plc. an American company?

Barinthus Biotherapeutics plc. is a US-based company headquartered in Germantown, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Barinthus Biotherapeutics plc. headquartered?

Barinthus Biotherapeutics plc. is headquartered in Germantown, Maryland, United States.

Is Barinthus Biotherapeutics plc. publicly traded?

Yes — Barinthus Biotherapeutics plc. is a publicly traded company. Its stock trades under the ticker symbol BRNS on the NASDAQ.

What does Barinthus Biotherapeutics plc. do?

Barinthus Biotherapeutics plc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore